Waters QTof Mass Spectrometer Detects Low-Level Compounds
The Waters Xevo G2-XS mass spectrometer is a new high-performance benchtop quadrupole time-of-flight (QTof) mass spectrometer that combines the new XS Collision Cell with the technologies of Tof-MRM, StepWave and QuanTof for sensitivity and selectivity that allows detection of low-level compounds.
The Waters Xevo G2-XS mass spectrometer is a new high-performance benchtop quadrupole time-of-flight (QTof) mass spectrometer that combines the new XS Collision Cell with the technologies of Tof-MRM, StepWave and QuanTof for sensitivity and selectivity that allows detection of low-level compounds.
The benchtop instrument allows laboratories to perform qualitative and quantitative experiments for both known and unknown analytes. For targeted quantitative experiments, Tof-MRM mode delivers a 10-fold improvement in signal-to-noise when compared to full scan mode, thus improving limits of detection and quantification. The instrument uses Waters MSE technology, a patented method of data acquisition that comprehensively catalogs complex samples in a single analysis.
ref="http://www.waters.com/qtof" target="_blank" ref="nofollow">Waters
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
